Magnesium sulfate and fetal neuroprotection: overview of clinical evidence.

ABSTRACT: Antenatal administration of magnesium sulfate is an important part of the neuroprotective strategy for preterm infants. Strong evidence from five randomized controlled trials and five meta-analyses has demonstrated that magnesium sulfate, when administered before preterm delivery, significantly reduces the risk of cerebral palsy at two years. Through secondary analyses of randomized controlled trials and other original clinical studies, this state-of-the-art review highlights the absence of serious adverse effects in both pregnant women and neonates, as well as the impact of maternal body mass index and preeclamptic status on the maternal and neonatal magnesium levels, which could influence the magnitude of the neuroprotective effect. Although antenatal magnesium sulfate is a cost-effectiv

SUBMITTER: Chollat C 

PROVIDER: S-EPMC6199933 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature